AstraZeneca’s China woes recede as focus shifts to upcoming readouts

# AstraZeneca's China Strategy Evolves:
Legal Challenges Recede as Major Investments Take Center Stage

AstraZeneca faces a possible fine of up to $8 million related to claims of illegal drug importation in China, but no action over allegations of infringing personal information3
The company announced a $2.5 billion investment in Beijing over the next five years to establish a new global strategic R&D center14
AstraZeneca completed the acquisition of FibroGen China, announced in their Q1 2025 results released on April 29, 20252
The Beijing R&D center will be AstraZeneca's sixth such center worldwide, featuring state-of-the-art AI and data science facilities4
The company signed significant biotech partnerships, including a $175 million upfront deal with Harbour BioMed that could reach $4.4 billion with milestone payments5
AstraZeneca's total potential investment in China could exceed $10 billion when including milestone payments5
The Beijing center is expected to grow AstraZeneca's workforce there to 1,700 employees4

Sources:

1. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-invests-2-and-half-bn-in-beijing-r-and-d-and-manufacturing.html

2. https://www.astrazeneca.com/content/dam/az/PDF/2025/q1/Q1-2025-results-announcement.pdf

3. https://firstwordpharma.com/story/5954804

4. https://www.biopharminternational.com/view/astrazeneca-invests-2-5-billion-establish-global-strategic-r-d-center-support-biotech-agreements-boost-manufacturing-china

5. https://www.biospace.com/business/astrazeneca-makes-up-to-10b-china-commitment-despite-political-pressure